Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 404-411 , September 2010

Cerebral atrophy, apolipoprotein E ɛ4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment

  • Ozioma C. Okonkwo

      Affiliations

    • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • Corresponding Author InformationCorresponding author. Tel.: 410-502-2188; Fax: 410-502-2189.
    • ,
  • Michael L. Alosco

      Affiliations

    • Neuropsychology Program, Rhode Island Hospital, Providence, RI, USA
    • ,
  • Beth A. Jerskey

      Affiliations

    • Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA
    • ,
  • Lawrence H. Sweet

      Affiliations

    • Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA
    • ,
  • Brian R. Ott

      Affiliations

    • Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA
    • ,
  • Geoffrey Tremont

      Affiliations

    • Neuropsychology Program, Rhode Island Hospital, Providence, RI, USA
    • Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA
    • ,
  • Alzheimer's Disease Neuroimaging Initiative

References 

  1. He W, Sengupta M, Velkoff VA, DeBarros KA. U.S. Census Bureau, Current Population Reports, P23-209. In: 65+ in the United States: 2005. Washington, DC: U.S. Government Printing Office; 2005;
  2. Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM, et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci. 2005;60:324–333
  3. Salthouse TA. Aging and measures of processing speed. Biol Psychol. 2000;54:35–54
  4. Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22:531–544
  5. Royall DR, Lauterbach EC, Kaufer D, Malloy P, Coburn KL, Black KJ. The cognitive correlates of functional status: a review from the committee on research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 2007;19:249–265
  6. Moye J, Marson DC. Assessment of decision-making capacity in older adults: an emerging area of practice and research. J Gerontol B Psychol Sci Soc Sci. 2007;62:P3–11
  7. Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectrums. 2008;13:45–53
  8. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388
  9. Busse A, Angermeyer MC, Riedel-Heller SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry. 2006;189:399–404
  10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Sask Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  11. APA. Diagnostic and statistical manual of mental disorders, 4th, text revision. Washington, DC: APA; 2000;
  12. Sluimer JD, van der Flier WM, Karas GB, Fox NC, Scheltens P, Barkhof F, et al. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology. 2008;248:590–598
  13. Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: comparative CSF study. Neurology. 2005;65:1502–1503
  14. Cahn-Weiner DA, Farias ST, Julian L, Harvey DJ, Kramer JH, Reed BR, et al. Cognitive and neuroimaging predictors of instrumental activities of daily living. J Int Neuropsychol Soc. 2007;13:747–757
  15. Marson DC, Sawrie SM, Snyder S, McInturff B, Stalvey T, Boothe A, et al. Assessing financial capacity in patients with Alzheimer disease: a conceptual model and prototype instrument. Arch Neurol. 2000;57:877–884
  16. Desai AK, Grossberg GT, Sheth DN. Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment. CNS Drugs. 2004;18:853–875
  17. Peres K, Chrysostome V, Fabrigoule C, Orgogozo JM, Dartigues JF, Barberger-Gateau P. Restriction in complex activities of daily living in MCI: impact on outcome. Neurology. 2006;67:461–466
  18. Tabert MH, Albert SM, Borukhova-Milov L, Camacho Y, Pelton G, Liu X, et al. Functional deficits in patients with mild cognitive impairment: prediction of AD. Neurology. 2002;58:758–764
  19. Aggarwal NT, Wilson RS, Beck TL, Bienias JL, Berry-Kravis E, Bennett DA. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Neurocase. 2005;11:3–7
  20. Spulber G, Niskanen E, Macdonald S, Smilovici O, Chen K, Reiman EM, et al. Whole brain atrophy rate predicts progression from MCI to Alzheimer's disease. Neurobiol Aging (in press).
  21. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005;1:55–66
  22. Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685–691
  23. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323–329
  24. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179–194
  25. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11–22
  26. Dickerson BC, Feczko E, Augustinack JC, Pacheco J, Morris JC, Fischl B, et al. Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. Neurobiol Aging. 2009;30:432–440
  27. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–355
  28. Bradley KM, Bydder GM, Budge MM, Hajnal JV, White SJ, Ripley BD, et al. Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease. Br J Radiol. 2002;75:506–513
  29. Bigler ED, Tate DF. Brain volume, intracranial volume, and dementia. Invest Radiol. 2001;36:539–546
  30. Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lu A, et al. Cerebral ventricular changes associated with transitions between normal cognitive function, mild cognitive impairment, and dementia. Alzheimer Dis Assoc Disord. 2007;21:14–24
  31. Bigler ED, Neeley ES, Miller MJ, Tate DF, Rice SA, Cleavinger H, et al. Cerebral volume loss, cognitive deficit and neuropsychological performance: comparative measures of brain atrophy: I. Dementia. J Int Neuropsychol Soc. 2004;10:442–452
  32. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–413
  33. Singer JD, Willett JB. Applied Longitudinal Data Analysis. New York, NY: Oxford University Press; 2003;
  34. Knopman D, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143–1153
  35. Okonkwo OC, Griffith HR, Belue K, Lanza S, Zamrini E, Harrell LE, et al. Medical decision-making capacity in patients with mild cognitive impairment. Neurology. 2007;69:1528–1535
  36. Braak E, Griffing K, Arai K, Bohl J, Bratzke H, Braak H. Neuropathology of Alzheimer's disease: what is new since A Alzheimer?. Eur Arch Psychiatry Clin Neurosci. 1999;249(Suppl 3):14–22
  37. Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology. 2003;61:487–492
  38. Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, et al. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol. 2002;59:1154–1160
  39. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron. 2001;32:181–184
  40. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci. 2008;9:768–778
  41. Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience. 1995;69:757–761
  42. Donahue JE, Johanson CE. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol. 2008;67:261–270
  43. Kivipelto M, Rovio S, Ngandu T, Kareholt I, Eskelinen M, Winblad B, et al. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med. 2008;12:2762–2771
  44. Melzer D, Dik MG, van Kamp GJ, Jonker C, Deeg DJ. The apolipoprotein E e4 polymorphism is strongly associated with poor mobility performance test results but not self-reported limitation in older people. J Gerontol A Biol Sci Med Sci. 2005;60:1319–1323
  45. Kaye JA. Methods for discerning disease-modifying effects in Alzheimer disease treatment trials. Arch Neurol. 2000;57:31–14
  46. Jack CR, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65:1227–1231
  47. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33–S39
  48. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology. 2005;65:119–124
  49. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J (in press).

 Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu/ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. ADNI investigators include (complete listing available at www.loni.ucla.edu/ADNI/Collaboration/ADNI_Citations.html).

PII: S1552-5260(10)00059-2

doi: 10.1016/j.jalz.2010.02.003

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 404-411 , September 2010

Article Tools

* Image Usage & Resolution